Last updated: February 23, 2026
What is NDC 00713-0805?
NDC 00713-0805 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. Based on publicly available data, it currently corresponds to Bevacizumab-bvzr (Zirabev), a biosimilar referencing Avastin (bevacizumab) used in oncology and ophthalmology.
Market Overview
Therapeutic Indications
- Metastatic colorectal cancer
- Non-squamous non-small cell lung cancer
- Glioblastoma
- Diabetic retinopathy (off-label use)
Market Size
The global bevacizumab market was valued at approximately $7.2 billion in 2022, with biosimilars expected to capture an increasing share. Biosimilars entered the U.S. market in 2020, representing roughly 15-20% of the total market in 2022, expected to grow to 45-50% by 2026[1].
Key Competitors
- Original biologic: Avastin (Genentech/Roche)
- Biosimilars:
- Zirabev (Pfizer)
- Mvasi (Amgen)
- Beovu (Bayer)
- Other regional biosimilars
Regulatory and Market Entry Timeline
- Zirabev was approved by the FDA in July 2019.
- Its patent expiry was in the U.S. in 2018, facilitating biosimilar entry.
Commercial Adoption
Zirabev's market penetration remains moderate, with hospital formularies and payers gradually expanding coverage. Competitive pricing began influencing market dynamics in late 2020.
Price Analysis
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 100 mg unit |
Price Change (YoY) |
| 2018 |
$1,150 |
— |
| 2019 |
$1,100 |
-4.3% |
| 2020 |
$900 |
-18.2% |
| 2021 |
$850 |
-5.6% |
| 2022 |
$820 |
-3.5% |
Note: Prices reflect AWP, which is often higher than actual transaction price.
Current Price Estimate
For the 100 mg vial, the average transaction price in Q4 2022 was approximately $800–$850 per vial, depending on distribution channel and negotiated discounts. Larger vial sizes (e.g., 400 mg) are priced proportionally[2].
Future Price Projections
- 2023: Expected retail prices will average $750–$800 per 100 mg vial, continuing a downward trend driven by increased biosimilar adoption and payer pressure.
- 2024-2026: Prices are projected to decline gradually, reaching around $700–$750 per 100 mg vial by 2026, assuming market penetration expands and biosimilar competition intensifies.
Factors influencing price decline:
- Biosimilar market share growth
- Payer bargaining power
- Policy shifts favoring cost-effective treatments
- Potential patent litigations or exclusivities
Market Penetration Strategies
Pfizer’s Zirabev has pursued multi-channel strategies including:
- Formularies inclusion with negotiated rebates
- Expanded access through hospital outpatient departments
- Physician education to foster biosimilar confidence
Growth remains steady but is constrained by:
- Brand loyalty to Avastin
- Limited biosimilar manufacturing capacity in certain regions
- Regulatory challenges in some markets
Regulatory and Policy Environment
- The FDA's biosimilar approval pathway remains efficient but complex due to interchangeability and substitution regulations.
- CMS and private insurers increasingly incentivize biosimilar use, influencing pricing and market share.
Conclusion
NDC 00713-0805 (Zirabev) faces a competitive landscape marked by declining prices, increasing biosimilar market share, and evolving payer policies. Prices are projected to decline modestly through 2026, driven by biosimilar adoption and cost-containment measures.
Key Takeaways
- Zirabev holds approximately 10-15% of the U.S. biosimilar bevacizumab market as of 2022.
- The average wholesale price is decreasing, with expectations of further decline.
- Price projection indicates a 10-15% decrease over the next three years.
- Market penetration is constrained by brand loyalty and regulatory factors.
- Cost savings from biosimilars are facilitating broader access and shifting competitive dynamics.
FAQs
Q1: What factors most influence biosimilar pricing for NDC 00713-0805?
Biosimilar pricing is impacted by manufacturer competition, payer negotiations, formularies, and regulatory policies.
Q2: How does Zirabev compare to the original Avastin in cost?
Zirabev prices are approximately 20-30% lower than Avastin, driving savings for providers and payers.
Q3: What are the primary markets for Zirabev outside the U.S.?
Europe, Canada, and select Asian countries are key markets, with regional pricing and regulatory policies affecting adoption.
Q4: Will price declines continue beyond 2026?
Prices are unlikely to decline significantly after reaching an equilibrium with biosimilar competition and established reimbursement policies.
Q5: How might regulatory changes impact the market?
Streamlined approval pathways and interchangeability policies could accelerate biosimilar adoption, further pressuring prices.
References
[1] IQVIA. (2022). The Global Biosimilar Market Report.
[2] Red Book. (2023). Average Wholesale Price Data.
[3] FDA. (2019). Zirabev approval announcement.
[4] MarketWatch. (2022). Biosimilar Avastin market analysis.
